Title
Clinical data analysis of telmisartan for hypertension management in Indian population
Authors
A Prem Kumar1, Anirudra Ghorai2, Vasudev Kriplani3, Rabindra Kumar Dash4, J Aravinda5, Paramesh Shamanna6, TK Sabeer7, Abdul Hannan8, Mahesh Abhyankar9* & Santosh Revankar9
Affiliation
1DiaPlus Clinic, Krishnammal Nagar, Fairlands, Salem, Tamilnadu- 636016, India; 2Divine nursing home, Taljuli Dr. Dandapat Complex, Kharagpur, West Bengal - 721301, India; 3Kriplani nursing Home, E-Ward, Tarabai Park, Kolhapur, Maharashtra - 416003, India; 4Gupta Diagnostic and Research Centre, Deulasahi, Bhanjpur, Baripada, Odisha - 757001, India; 5Dr.Aravind's Diabetes Center, No. 14 & 15, 7th Main, 3rd Block, 4th Stage, BasaveshwarNagar, Bengaluru, Karnataka-560079, India; 6Bangalore Diabetes Centre, No. 426, 4th Cross Rd, HBR Layout 2nd Block, Stage 1, Kalyan Nagar, Bengaluru, Karnataka 560043, India; 7Diacare, 2nd Floor, Chamber Plaza, Thayatheru Rd, Thayatheru, Thana, Kannur, Kerala-670002, India; 8Dr. Hamdulay's Cardiac Rehabilitation Centre, 233/234, Bellasis Road, Junction, Nagpada, Mumbai - 400008, India; 9USV Private Limited, BSD Marg, Station Road, Deonar, Govandi East, Mumbai, Maharashtra - 400088, India.
Corresponding author: Dr. Mahesh Abhyankar - Email: dr.mabhyankar@gmail.com; Tel: +91-98670 03903; Dr Mahesh Abhyankar - drmahesh.abhyankar@usv.in; Dr Santosh Revankar - santosh.revankar@usv.in
Article Type
Research Article
Date
Received May 9, 2021; Revised June 23, 2021; Accepted June 23, 2021, Published June 30, 2021
Abstract
It is of interest to evaluate the clinical characteristics, treatment patterns, clinical effectiveness, and safety of telmisartan as a monotherapy or as part of combination therapy in Indian adults (>18 years old) with hypertension. All patients were receiving telmisartan as monotherapy, or as a combination therapy for hypertension management. Demographics, risk factors, existing comorbidity, and ongoing medical therapies were retrieved from the patients’ medical records. A total of 8607 patients with hypertension (median age, 51.0 years) were part of the study. The gender distribution suggested, 5534(64.3%) patients were male, and 3073 (35.7%) were female patients. The excess salt intake (39.0%) was the most common risk factor according to the results. The analysis revealed telmisartan dual therapy (57.9%) as the most prescribed therapy, followed by monotherapy (32.5%), and triple therapy (9.6%). Further, telmisartan 40mg (21.3%) and telmisartan 40mg plus amlodipine 5mg (17.6%) were the most commonly prescribed therapies. The data suggested that only 17.2% of patients required dose titration. The mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) (mmHg) were significantly decreased with monotherapy (mean change: 19.8 [15.1] mmHg and 8.8[8.2] mmHg), dual therapy (mean change: 23.7 [16.6] mmHg and 10.3[8.5] mmHg), and triple therapy (mean change: 28.6 [19.0] mmHg and 12.1[10.8] mmHg) after the treatment (P<0.001). A total of 98.4% of the patients were compliant, and 97.6% achieved the target blood pressure goal with telmisartan-based therapy. There were 157 adverse events reported altogether. The Physicians’ global evaluation of efficacy and tolerability showed the majority of the patients receiving telmisartan-based therapy on a good to excellent scale. Telmisartan used as a monotherapeutic agent or as a part of combination therapy was successful and effective in reducing blood pressure and achieving the blood pressure target. Irrespective of the patient’s age, duration, and stages of hypertension, the study resulted in a good to excellent scale in efficacy and tolerability in the Indian patients having hypertension.
Keywords
Hypertension, Telmisartan, Blood pressure, therapeutic compliance, combinatorial therapy.
Citation
Prem Kumar et al. Bioinformation 17(6): 652-659 (2021)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
